Back to Journals » OncoTargets and Therapy » Volume 10

Arterial stiffness in hematologic malignancies

Authors Mozos I, Borzak G, Caraba A, Mihaescu R

Received 6 November 2016

Accepted for publication 14 January 2017

Published 3 March 2017 Volume 2017:10 Pages 1381—1388

DOI https://doi.org/10.2147/OTT.S126852

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Ioana Mozos,1 Georgiana Borzak,2 Alexandru Caraba,3 Rodica Mihaescu3

1Department of Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 2Department of Hematology, “Oncohelp” Hospital, 3First Department of Internal Medicine, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania

Abstract: Malignant and cardiovascular disorders are the top causes of mortality worldwide. This article reviews the main literature data and mechanisms linking hematologic malignancies and arterial stiffness, focusing on recent experimental and clinical results. Several links were found in hematologic malignancies between complete blood count and arterial stiffness. Chemotherapy, especially anthracyclines, cyclophosphamide and tyrosine kinase inhibitors, as well as radiotherapy and hematopoietic stem cell transplantation are the main known causes of arterial stiffness increase in hematologic malignancies. The mechanisms of arterial stiffness elevation in hematologic malignancies include an increased oxidative stress, impaired vascular wall homeostasis, endothelial dysfunction and apoptosis of endothelial cells, overexpression of inflammatory cytokines, accelerated atherosclerosis, increased blood viscosity and unstable platelet aggregates. Guidelines regarding cardiovascular health screening and cardiovascular risk scores are necessary for hematologic cancer survivors in order to improve prognosis and quality of life of the patients.

Keywords: arterial stiffness, complete blood count, leukemia, lymphoma, multiple myeloma, chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Therapy with pamidronate in children with osteogenesis imperfecta

Marginean O, Tamasanu RC, Mang N, Mozos I, Brad GF

Drug Design, Development and Therapy 2017, 11:2507-2515

Published Date: 28 August 2017